Trump's generic drug tariff threats put Sandoz in the crosshairs

Donald Trump's announcement of steep tariffs on imported generic drugs, set to begin in August 2028 and escalate the following year, places Swiss pharmaceutical giant Sandoz in a precarious position. The former U.S. president aims to pressure drug manufacturers into bringing their production back to American soil.

Sandoz, a global leader in generic and biosimilar medicines, is particularly vulnerable as it lacks any production facilities within the United States. The company has instead concentrated its manufacturing capabilities in Europe, with significant operations in Slovenia and Austria, and also relies on a Canadian partner. This operational structure mirrors a broader industry trend where production has shifted from high-cost countries to nations like India, now the world's leading exporter of generic drugs.

The proposed tariffs, escalating from 100% to 200%, could significantly impact Sandoz's business model, which is built on globalized production networks. The company's strategic focus on European manufacturing, while efficient for cost management, leaves it exposed to such protectionist trade measures.